News

FDA taps Icon to help patients better weigh in on trials

Many clinical trials rely on patient-reported outcomes to determine whether drugs are working, but with disparate methods employed across the industry, it can be difficult to compare the results from one study with those of another. With that in mind, the FDA has recruited CRO giant Icon to help develop an industry standard for patient polling in antibacterial R&D.

PPD teams up with Medidata on risk-based monitoring

PPD has expanded its relationship with eClinical outfit Medidata, combining technologies in risk-based monitoring to help sponsors use real-time safety data to make decisions on clinical trials.

AMRI tanks on disappointing sales and a dimmer outlook

Contract drug developer AMRI watched its shares plummet after underperforming in the third quarter, an earnings miss the company blamed on declining demand, spiking costs and bad weather in the desert.

WuXi reaches into Israel with a new office and a local partnership

Chinese CRO WuXi PharmaTech has opened up shop in Israel, cutting the ribbon on a Tel Aviv outpost and aligning itself with a local investor to expand its presence in the country.

PRA raises the stakes, eyeing $400M in a blockbuster IPO

CRO conglomerate PRA is angling to be the next contract drug developer to make a splash on Wall Street, setting terms for a $400 million IPO.

CRO Paragon raises $13M to expand its footprint

Baltimore CRO Paragon Bioservices has raised a $13 million A round, money it'll spend to stretch out its offerings in biologics R&D and manufacturing.

LabCorp is buying Covance for $5.6B to cut in on the CRO boom

Diagnostics giant LabCorp is buying its way into the upper ranks of the CRO business, signing a deal to pay $5.6 billion for Covance and create an end-to-end testing conglomerate.

Timely deals boost Charles River's balance sheet

A string of acquisitions has revenue rolling at Charles River Laboratories, and the CRO has inked another M&A deal it hopes will pay off with a larger market share.

Quintiles posts another $1B quarter and dials up its expectations

Quintiles, the world's largest CRO, is rolling toward its biggest year yet on the heels of a fourth straight quarter with more than $1 billion in sales.

SRI's CRO cuts the ribbon on a new early-phase outpost

SRI International's in-house CRO has opened up a new Phase I center, expanding its footprint in the market for early-stage research.

InVentiv turns to Veeva for cloud-based trial tech

CRO inVentiv Health is dumping out its own trial document storage system and replacing it with Veeva Systems' cloud-based platform, a move the eClinical provider touts as a major affirmation of its technology.

MPI buys out a CRO neighbor to bolster early-stage R&D

MPI Research has acquired fellow Michigan CRO Jasper Clinical Research and Development for an undisclosed sum, a move that will augment the company's offerings in Phase I trials.

CROs line up to advise Big Pharma's R&D think tank

The Association of Clinical Research Organizations, which represents the world's largest CROs, is putting together a sort of contractors' council to weigh in on the efforts of TransCelerate BioPharma, a nonprofit group run by the biggest names in drug development.

WuXi teams up with Foundation Medicine to bring cancer profiling to China

WuXi PharmaTech has struck a deal with the genomics experts at Foundation Medicine, signing on to offer the company's cancer-decoding services to drug developers in its native China.

Icon posts another revenue jump and dials up its expectations

CRO giant Icon charted double-digit revenue growth in the third quarter, chugging toward its best-ever year and lifting its earnings projections in the process.

Big CROs are booming, but can it last?

The world's largest CROs are reaping the benefits of two major market trends: Big Pharma is finally getting back to spending big on R&D after some lean years post-downturn, and biotech is enjoying a protracted bit of bullishness that has lined pockets around the industry.

Charles River debuts new testing tech for quality control

Charles River Laboratories has unveiled a new technology it says can better test for impurities by combining two common methods into a single product, making for a flexible solution.

A glitch in bioequivalence software puts trial results in doubt

Observed glitches with Thermo Fisher's popular drug development software have led to concerns that data used to win approvals may have been faulty, and the company is working alongside regulators to figure out just how widespread the issue may be.

Roche taps DKSH to move its products in Asia

DKSH, a well-heeled pharma marketing operation, has reupped with Roche, expanding a long-standing agreement to include more of Asia.

PPD pairs off with Sellas to pick up the pipeline pace

PPD has signed a master service agreement with Swiss biotech Sellas, lending its drug development expertise to the company's efforts to advance a portfolio of treatments.